The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
doi 10.18027/2224-5057-2017-7-4-42-47
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Russian Society of Clinical Oncology

Related search

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer

Clinical Cancer Reviews
2009English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides

JAMA Dermatology
DermatologyMedicine
2016English

P3-027Liver Cirrhosis Associated With Paclitaxel and Bevacizumab Combination Therapy in a Metastatic Breast Cancer Patient

Annals of Oncology
MedicineOncologyHematology
2018English

The Main Parameters of Cellular Immunity in Patients With Triple-Negative Breast Cancer: Relationship With Efficiency of Chemotherapy

Medical Immunology (Russia)
AllergyImmunology
2018English

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Immediate and Long-Term Outcomes of Drug Treatment in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2018English

Chemotherapy in Combination With Bevacizumab in Breast Cancer. Results of the Observational Study in Daily Clinical Practice

Malignant tumours
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy